Lupin Earns CDP Double 'A' Rating for Climate Action, Water Security Leadership

Published On 2026-01-25 05:30 GMT | Update On 2026-01-25 05:31 GMT

Mumbai: Global pharma major Lupin Limited (Lupin) has announced that it has received the highest 'A' leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition affirms Lupin's position among distinguished global leaders who champion sustainability and transparency at the highest level.

Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability and proactive initiatives aimed at mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. This represents a substantial enhancement compared to Lupin’s 2024 ratings of ‘A-’ in both categories, as well as the ratings of ‘B’ in 2023 for climate and ‘C’ for water, thereby reflecting significant year-over-year progress.

Also Read: Lupin Expands GLP-1 Portfolio with Galenicum Semaglutide Deal

Commenting on this achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin, said, “As a global pharma leader, we have significantly advanced our efforts to reduce environmental impact through innovation, collaboration, and transparency. We are proud to have earned CDP’s Double ‘A’ rating. CDP’s strict framework has helped shape and accelerate our climate initiatives, fostering ongoing progress. We are committed to establishing new sustainability standards and generating lasting value for our communities and the planet.”

Lupin has not only received recognition from CDP but also achieved an S&P Global ESG score of 91 in 2025. This is a best-in-class global achievement, positioning Lupin among a distinguished group of companies worldwide that have surpassed the 90-point threshold.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

sheeba farhat

Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Lupin Earns CDP Double 'A' Rating for Climate Action, Water Security Leadership

Similar News

Alkem Labs Slapped Rs 2.34 Cr GST Demand in Goa

USFDA Closes Inspection at Zydus Ankleshwar Unit-2 With Three Observations

Akums Drugs Secures EU-GMP Certification for Two Haridwar Plants

Abbott's Phensedyl Supply Chain Under Scanner After Ghaziabad Seizure, Codeine Diversion Probe Widens

Cipla Reappoints P R Ramesh as Independent Director for Second Term Till 2031

No Monopoly Over Alphabets: Delhi HC Rejects Alkem's 'A TO Z' Trademark Claim

CDSCO Clears Over 100 rDNA Drugs and Biologics Between 2020-25, Boosting Access to Advanced Therapies